Correlation Between AIM ImmunoTech and ABVC Biopharma

Can any of the company-specific risk be diversified away by investing in both AIM ImmunoTech and ABVC Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AIM ImmunoTech and ABVC Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between AIM ImmunoTech and ABVC Biopharma, you can compare the effects of market volatilities on AIM ImmunoTech and ABVC Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AIM ImmunoTech with a short position of ABVC Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of AIM ImmunoTech and ABVC Biopharma.

Diversification Opportunities for AIM ImmunoTech and ABVC Biopharma

-0.13

Correlation Coefficient

AIM ImmunoTech  ABVC Biopharma

Good diversification

The 3 months correlation between AIM and ABVC is -0.13. Overlapping area represents the amount of risk that can be diversified away by holding AIM ImmunoTech and ABVC Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ABVC Biopharma and AIM ImmunoTech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AIM ImmunoTech are associated (or correlated) with ABVC Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ABVC Biopharma has no effect on the direction of AIM ImmunoTech i.e., AIM ImmunoTech and ABVC Biopharma go up and down completely randomly.

Pair Corralation between AIM ImmunoTech and ABVC Biopharma

Considering the 90-day investment horizon AIM ImmunoTech is expected to under-perform the ABVC Biopharma. In addition to that, AIM ImmunoTech is 1.01 times more volatile than ABVC Biopharma. It trades about -0.12 of its total potential returns per unit of risk. ABVC Biopharma is currently generating about 0.16 per unit of volatility. If you would invest  146.00  in ABVC Biopharma on May 14, 2025 and sell it today you would earn a total of  149.00  from holding ABVC Biopharma or generate 102.05% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.39%
Values	Daily Returns

AIM ImmunoTech  vs.  ABVC Biopharma

AIM ImmunoTech

Risk-Adjusted Performance

Weakest

Over the last 90 days AIM ImmunoTech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in September 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

ABVC Biopharma

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in ABVC Biopharma are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, ABVC Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with AIM ImmunoTech and ABVC Biopharma

The main advantage of trading using opposite AIM ImmunoTech and ABVC Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AIM ImmunoTech position performs unexpectedly, ABVC Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABVC Biopharma will offset losses from the drop in ABVC Biopharma's long position.

The idea behind AIM ImmunoTech and ABVC Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.